IPO - Profile


We are a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Certain nucleotide repeat expansion diseases, such as Friedreich ataxia (FA), can result in reduced expression of specific mRNAs; in other diseases, such as myotonic dystrophy type-1 (DM1), Fuchs endothelial corneal dystrophy (FECD), and Huntington disease, the nucleotide repeat expansions result in the generation of toxic gene products, often associated with pathological nuclear foci. Our GeneTACs are designed More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$20.00 12,000,000 Positive High 4.02%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 25 Mar, 2021

Offer 26 Mar, 2021

Look Ahead

Lock Up Expiry Sep 26, 2021

IPO Terms

Offer Price $20.00
Offer Size 12M

Market Sentiments

Stock Price